posted on 2022-01-06, 22:37authored bySusan Martin, Elena P Sorokin, E. Louise Thomas, Naveed Sattar, Madeleine Cule, Jimmy D Bell, Hanieh Yaghootkar
<b>Objective:</b> Fat content and volume of liver and pancreas
are associated with risk of diabetes in observational studies; whether these
associations are causal is unknown. We conducted a Mendelian randomization (MR)
study to examine causality of such associations.
<p> </p>
<p><b>Research design and methods:</b> We used genetic variants associated (p <
5×10<sup>−8</sup>) with the exposures (liver and pancreas volume and fat
content) using MRI scans of UK Biobank participants (n=32,859). We obtained summary-level
data for risk of type 1 (9,358 cases) and type 2 (55,005 cases) diabetes from
the largest available genome-wide association studies. We performed inverse-variance
weighted MR as main analysis and several sensitivity analyses to assess
pleiotropy and to exclude variants with potential pleiotropic effects. </p>
<p> </p>
<p><b>Results:</b> Observationally, liver fat and volume were
associated with type 2 diabetes (odds ratio (OR) per one standard deviation
(SD) higher exposure 2.16 [2.02 - 2.31] and 2.11 [1.96, 2.27], respectively). Pancreatic
fat was associated with type 2 diabetes (1.42 [1.34, 1.51]) but not type 1
diabetes, and pancreas volume was negatively associated with type 1 diabetes
(0.42 [0.36, 0.48]) and type 2 diabetes (0.73 [0.68, 0.78]). MR analysis
provided evidence only for a causal role of liver fat and pancreas volume on
risk of type 2 diabetes (1.27 [1.08,1.49] or 27% increased risk and 0.76
[0.62,0.94] or 24% decreased risk per 1SD, respectively) and no causal
associations with type 1 diabetes.</p>
<p> </p>
<p><b>Conclusions:</b> Our findings assist in understanding the
causal role of ectopic fat in the liver and pancreas and of organ volume in the
pathophysiology of type 1 and 2 diabetes.</p>
<p> </p>
Funding
H.Y. is funded by Diabetes UK RD Lawrence fellowship (grant: 17/0005594). S.M. is funded by the MRC. M.C., E.P.S. are funded by Calico Life Sciences LLC. NS is supported by the British Heart Foundation Research Excellence Award (RE/18/6/34217).